Zidovudine-based lytic-inducing chemotherapy for Epstein-Barr virus-related lymphomas

Leukemia and Lymphoma

Volumn 55, Issue 4, 2014, Pages 786-794

  Bayraktar, Ulas Darda ^a   Diaz, Luis A ^a   Ashlock, Brittany ^a   Toomey, Ngoc ^a   Cabral, Lisa ^a   Bayraktar, Soley ^a   Pereira, Denise ^a   Dittmer, Dirk P ^b   Ramos, Juan Carlos ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Epstein Barr virus; Human immunodeficiency virus; Non Hodgkin lymphoma; Plasmablastic lymphoma; Primary central nervous system lymphoma; Zidovudine

Indexed keywords

DOXORUBICIN; HYDROXYUREA; METHOTREXATE; ZIDOVUDINE; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT;

ADULT; APOPTOSIS; ARTICLE; BURKITT LYMPHOMA; CLINICAL ARTICLE; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; EPSTEIN BARR VIRUS INFECTION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; MALE; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIMARY EFFUSION LYMPHOMA; PRIORITY JOURNAL; TREATMENT RESPONSE; CANCER STAGING; COMPLICATION; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFECTS; EPSTEIN BARR VIRUS; LYMPHOMA; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; REMISSION; RETROSPECTIVE STUDY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT OUTCOME; TUMOR CELL LINE;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIVIRAL AGENTS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOMA; MALE; METHOTREXATE; MIDDLE AGED; NEOPLASM STAGING; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; ZIDOVUDINE;

EID: 84903546113     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.818142     Document Type: Article

References (45)

1. Shibata D, Weiss LM, Hernandez AM, et al. Epstein-Barr virus- associated non-Hodgkin's lymphoma in patients infected with the human immunodeficiency virus. Blood 1993;81:2102-2109. (Pubitemid 23106725)
2. Delecluse HJ, Anagnostopoulos I, Dallenbach F, et al. Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood 1997;89:1413-1420. (Pubitemid 27080006)
3. Carbone A, CesarmanE, SpinaM, et al. HIV-associated lymphomas and gamma-herpesviruses. Blood 2009; 113: 1213-1224.
4. Cesarman E, Mesri EA. Pathogenesis of viral lymphomas. Cancer Treat Res 2006;131:49-88.
5. Thorley-Lawson DA, Gross A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med 2004;350:1328-1337. (Pubitemid 38375368)
6. Kulwichit W, Edwards RH, Davenport EM, et al. Expression of the Epstein-Barr virus latent membrane protein 1 induces B cell lymphoma in transgenic mice. Proc Natl Acad Sci USA 1998;95:11963-11968. (Pubitemid 28460522)
7. Mentzer SJ, Fingeroth J, Reilly JJ, et al. Arginine butyrate-induced susceptibility to ganciclovir in an Epstein-Barr-virus-associated lymphoma. Blood Cells Mol Dis 1998; 24: 114-123. (Pubitemid 28365731)
8. Di Renzo L, Avila-Carino J, Klein E. Induction of the lytic viral cycle in Epstein Barr virus carrying Burkitt lymphoma lines is accompanied by increased expression of major histocompatibility complex molecules. Immunol Lett 1993;38:207-214. (Pubitemid 24022934)
9. Moore SM, Cannon JS, Tanhehco YC, et al. Induction of Epstein- Barr virus kinases to sensitize tumor cells to nucleoside analogues. Antimicrob Agents Chemother 2001; 45: 2082-2091. (Pubitemid 32591702)
10. Feng WH, Hong G, Delecluse HJ, et al. Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas. J Virol 2004;78: 1893-1902. (Pubitemid 38176721)
11. Gustafson EA, ChillemiAC, Sage DR, et al. TheEpstein-Barrvirus thymidine kinase does not phosphorylate ganciclovir or acyclovir and demonstrates a narrow substrate specificity compared to the herpes simplex virus type 1 thymidine kinase. Antimicrob Agents Chemother 1998; 42: 2923-2931. (Pubitemid 28501227)
12. Kurokawa M, Ghosh SK, Ramos JC, et al. Azidothymidine inhibits NF-kappaB and induces Epstein-Barr virus gene expression in Burkitt lymphoma. Blood 2005; 106: 235-240. (Pubitemid 40967198)
13. Ramos JC, Sin SH, Staudt MR, et al. Nuclear factor kappa B pathway associated biomarkers in AIDS defining malignancies. Int J Cancer 2012; 130: 2728-2733.
14. Tosi P, Calabresi P, Goulette FA, et al. Azidothymidine-induced cytotoxicity and incorporation into DNA in the human colon tumor cell line HCT-8 is enhanced by methotrexate in vitro and in vivo. Cancer Res 1992; 52: 4069-4073.
15. Lima RT, Seca H, Bras S, et al. Treatment of Akata EBV-positive cells with doxorubicin causes more EBV reactivation than treatment with etoposide. Chemotherapy 2011; 57: 195-203.
16. Wynn HE, Brundage RC, Fletcher CV. Clinical implications of CNS penetration of antiretroviral drugs. CNS Drugs 2002;16:595-609.
17. Sarker D, Thirlwell C, Nelson M, et al. Leptomeningeal disease in AIDS-related non-Hodgkin 's lymphoma. AIDS 2003; 17: 861-865. (Pubitemid 36547658)
18. Tosi P, GherlinzoniF, MazzaP, et al. 3'-Azido3'-deoxythymidine + methotrexate as a novel antineoplastic combination in the treatment of human immunodeficiency virus-related non-Hodgkin ' s lymphomas.Blood 1997;89:419-425. (Pubitemid 27051676)
19. Raez L, Cabral L, Cai JP, et al. Treatment of AIDS-related primary central nervous system lymphoma with zidovudine, ganciclovir, and interleukin 2.AIDS Res Hum Retroviruses 1999; 15: 713-719. (Pubitemid 29237394)
20. Ghosh SK, Wood C, Boise LH, et al. Potentiation of TRAIL- induced apoptosis in primary effusion lymphoma through azidothymidine-mediated inhibition of NF-kappa B. Blood 2003; 101: 2321-2327. (Pubitemid 36302077)
21. Lee RK, Cai JP, Deyev VV, et al. Azidothymidine and interferon- alpha induce apoptosis in herpesvirus-associated lymphomas. Cancer Res 1999; 59: 5514-5520. (Pubitemid 29526467)
22. Uldrick TS, Polizzotto MN, Aleman K, et al. High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy.Blood 2011; 117: 6977-6986.
23. Roychowdhury S, Peng R, Baiocchi RA, et al. Experimental treatment of Epstein-Barr virus-associated primary central nervous system lymphoma. Cancer Res 2003;63:965-971. (Pubitemid 36278426)
24. Little RF. Highly effective treatment ofacquiredimmunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology.Blood 2003; 101:4653-4659. (Pubitemid 36857717)
25. Cortes J, Thomas D, Rios A, et al. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. Cancer 2002; 94: 1492-1499. (Pubitemid 34212643)
26. Toomey NL, Deyev VV, Wood C, et al. Induction of a TRAIL- mediated suicide program by interferon alpha in primary effusion lymphoma. Oncogene 2001; 20: 7029-7040. (Pubitemid 33052195)
27. Ryan JL, Fan H, Glaser SL, et al. Epstein-Barr virus quantitation by real-time PCR targeting multiple gene segments: a novel approach to screen for the virus in paraffin-embedded tissue and plasma. J Mol Diagn 2004;6:378-385. (Pubitemid 39517407)
28. Tang W, Harmon P, Gulley ML, et al. Viralresponseto chemotherapy in endemic burkitt lymphoma. Clin Cancer Res 2010; 16: 2055-2064.
29. Navarro JT, Lloveras N, Ribera JM, et al. The prognosis of HIV- infected patients with diffuse large B-cell lymphoma treated with chemotherapy and highly active antiretroviral therapy is similar to that of HIV-negative patients receiving chemotherapy. Haematologica 2005; 90: 704-706. (Pubitemid 40780899)
30. Bayraktar S, Bayraktar UD, Ramos JC, et al. Primary CNS lymphoma in HIV positive and negative patients: comparison of clinical characteristics, outcome and prognostic factors. J Neurooncol 2011; 101: 257-265.
31. Castillo J, Pantanowitz L, Dezube BJ. HIV-associated plasmablastic lymphoma: Lessons learned from 112 published cases. Am J Hematol 2008; 83: 804-809.
32. Weiss R, Mitrou P, Arasteh K, et al. Acquired immunodeficiency syndrome-related lymphoma: Simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival. Cancer 2006;106:1560-1568.
33. MacMahon EM, Glass JD, Hayward SD, et al. Epstein-Barr virus in AIDS-related primary central nervous system lymphoma. Lancet 1991; 338: 969-973.
34. Baumgartner JE, Rachlin JR, Beckstead JH, et al. Primary central nervous system lymphomas: natural history and response to radiation therapy in 55 patients with acquired immunodeficiency syndrome. JNeurosurg 1990;73:206-211. (Pubitemid 20238500)
35. Skiest DJ, Crosby C. Survival is prolonged by highly active antiretroviral therapy in AIDS patients with primary central nervous system lymphoma. AIDS 2003; 17: 1787-1793. (Pubitemid 37000096)
36. Kreisl T, Panageas KS, Elkin EB, et al. Treatment patterns and prognosis in patients with human immunodeficiency virus and primary central nervous system lymphoma. Leuk Lymphoma 2008; 49: 1710-1716.
37. Aboulafia DM, Ratner L, Miles SA, et al. Antiviral and immunomodulatory treatment for AIDS-related primary central nervous system lymphoma: AIDS Malignancies Consortium pilot study 019. Clin Lymphoma Myeloma 2006;6:399-402.
38. Shewach DS, Lawrence TS. Antimetabolite radiosensitizers. J Clin Oncol 2007;25:4043-4050. (Pubitemid 47492948)
39. Cannon JS, Hamzeh F, Moore S, et al. Human herpesvirus 8-encoded thymidine kinase and phosphotransferase homologues confer sensitivity to ganciclovir. J Virol 1999;73:4786-4793. (Pubitemid 29246738)
40. Martin JC, Dvorak CA, Smee DF, et al. 9- [(1, 3-Dihydroxy- 2-propoxy)methyl] guanine: a new potent and selective antiherpes agent. J Med Chem 1983; 26: 759-761. (Pubitemid 13079360)
41. Staudt MR, KananY, Jeong JH, et al. Thetumormicroenvironment controls primary effusion lymphoma growth in vivo. Cancer Res 2004;64:4790-4799. (Pubitemid 38924522)
42. Meng Q, Hagemeier SR, Fingeroth JD, et al. The Epstein-Barrvirus (EBV)-encoded protein kinase, EBV-PK, but not the thymidine kinase (EBV-TK), is required for ganciclovir and acyclovir inhibition of lytic viral production.J Virol 2010; 84: 4534-4542.
43. Westphal EM, Blackstock W, Feng W, et al. Activation of lytic Epstein-Barr virus (EBV) infection by radiation and sodium butyrate in vitro and in vivo: a potential method for treating EBV-positive malignancies. Cancer Res 2000; 60: 5781-5788.
44. Ghosh SK, Perrine SP, Williams RM, et al. Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents. Blood 2012; 119: 1008-1017.
45. Perrine SP, Hermine O, Small T, et al. A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood 2007; 109: 2571-2578. (Pubitemid 46425904)